Umbilical cord blood (UCB) has increased access to hematopoietic cell transplantation (HCT) for patients without HLA-matched sibling donors (MSD). We compared outcomes of HCT using MSD (N ¼ 38) or UCB (N ¼ 60) among older patients (age X55 years) with AML or myelodysplastic syndromes (MDS). All patients received a reduced intensity regimen consisting of CY, fludarabine and 200 cGy TBI. Median age at HCT was 63 years for MSD and 61 years for UCB recipients. Among UCB recipients, 95% received two UCB units and 88% received 1-2 locus HLA-mismatched units to optimize cell dose. OS at 3-years was 37% for MSD and 31% for UCB recipients (P ¼ 0.21). On multivariate analysis, donor source (MSD vs UCB) did not impact risks of OS, leukemia-free survival and relapse or treatmentrelated mortality. UCB is feasible as an alternative donor source for reduced-intensity conditioning HCT among older patients with AML and MDS who do not have a suitable MSD.
Introduction
AML and myelodysplastic syndromes (MDS) occur most commonly in older patients. For many older patients with high-risk AML and MDS, allogeneic hematopoietic cell transplantation (HCT) offers the best chance of long-term survival. HCT has traditionally been underutilized in older patients because of the perceived higher risks of transplant complications. A recent large analysis reported comparable outcomes of HCT using reduced-intensity conditioning (RIC) regimens and either related or unrelated donors among older patients with AML and MDS, indicating that age alone is not a contraindication to HCT. 1 Availability of a suitable donor is a major barrier to successful HCT in older patients. Unrelated umbilical cord blood (UCB) has been increasingly accepted as an alternative donor source for patients without a HLAidentical matched sibling donor (MSD) or a HLA-matched unrelated donor. [2] [3] [4] [5] [6] [7] Although smaller studies have highlighted the feasibility of UCB for HCT in older patients, its use for treatment of AML and MDS in this population has not been well described. 8, 9 We hypothesized that for older patients with AML and MDS lacking a MSD, UCB could lead to comparable survival, thus extending the availability of HCT for patients who would otherwise be ineligible because of donor availability. To evaluate this question, we compared the safety and efficacy of RIC HCT using either MSD or UCB in patients X55 years.
Materials and methods
Data were collected prospectively for 98 consecutive patients aged X55 years who received RIC HCT using either MSD or UCB for AML or MDS between 2001 and 2009. All received HCT using RIC because of their older age. Our cohort included 38 MSD HCT recipients and 60 patients with no HLA-matched related donors who received UCB HCT.
All MSD grafts were 6/6 HLA matched (Ag level at HLA-A, B and DRB1) and used a minimum cell dose of 3 Â 10 6 CD34 þ cells/kg; all patients received filgrastimmobilized peripheral blood grafts. Using UCB selection criteria that we have previously published, 3, 5, 10 UCB grafts were matched at 4-6 of 6 HLA-A, -B (Ag level) and -DRB1 (allele level) to the recipient, and in patients receiving two UCB units, to each other. A total of 56 (95%) UCB HCT recipients received two UCB units and 53 (88%) received at least 1-2 HLA-mismatched units.
Pre-transplantation comorbidities were scored retrospectively for all patients using the HCT-specific comorbidity index (HCT CI) described by Sorror et al., 11 and were categorized as low-risk (score 0), intermediate-risk (score 1-2) and high-risk (score X3).
The RIC regimen for all patients consisted of CY (50 mg/ kg i.v. on day À6), fludarabine (40 mg/m 2 i.v. daily from days À6 through À2) and TBI (200 cGy on day À1). Equine anti-thymocyte globulin 15 mg/kg i.v. every 12 h for six doses was added to a subgroup of patients who had not received chemotherapy within 3 months of HCT or a previous autologous transplant (n ¼ 46). All patients received GVHD prophylaxis with CYA(from days À3 to þ 180) and mycophenolate mofetil (from days À3 to þ 30). Filgrastim was administered to all patients from day þ 1 until the ANC was more than 2.5 Â 10 9 /L for 2 days. Treatment protocols were approved by the University of Minnesota institutional review board, registered at http://clinicaltrials. gov and all patients gave informed consent before HCT.
Donor chimerism was determined serially on marrow and/or blood samples on days þ 21-28, þ 60, þ 100, 6 months and then annually after HCT. Chimerism analysis was performed using quantitative PCR of informative polymorphic VNTR or STR regions in recipient and donor. 10 The primary endpoint was probability of OS. Secondary study endpoints included probability of leukemia-free survival (LFS) and cumulative incidences of acute and chronic GVHD, relapse, treatment-related mortality (TRM), and neutrophil engraftment. LFS was defined as survival in continuous CR. TRM was defined as death following HCT without disease progression or relapse. Standard clinical criteria were used to diagnose and grade GVHD. 12, 13 We also compared absolute lymphocyte count recovery (ALC) between the two donor sources. ALC was recorded for day 14, 28, 60 and 100 post-transplantation for patients who were alive and disease-free at these time points.
Comparison of patient and transplant characteristics was performed using w 2 , Fisher's exact or Wilcoxon's rank sum test as appropriate. Cumulative incidence estimates of TRM and GVHD considered relapse as a competing risk.
14 The Kaplan-Meier method was used to plot survival curves for OS and LFS. 15 Multivariable Cox regression analyses were performed for OS and LFS, 15 and multivariable FineGray regression analyses for relapse and TRM. 16 All multivariate models included donor type (MSD vs UCB) and were adjusted for disease status (AML in CR1 vs AML not in CR1 vs MDS) and HCT-CI score (low vs intermediate vs high). Event times were measured from date of transplantation to date of death or last contact. Analysis was performed with follow-up through August 2010.
All P-values were two sided. Analyses were performed in SAS 9.2 (Cary, NC, USA). A total of 37 patients included in this analysis have been reported in a previous analysis of RIC HCT in older patients from our center. 8 Results Table 1 describes demographic characteristics of our cohort. The median follow-up of survivors was 2.8 years (range, 1-6 years). Among 70 patients with AML, all were in CR at the time of HCT. The majority received HCT in CR1 (59%) and fewer were in CR2 (26%) or CR3 þ (16%) at the time of transplantation. Cytogenetic risk at diagnosis was good, intermediate and poor in 3%, 53% and 43% AML patients, respectively. 17 Among MDS patients (N ¼ 28), 32% had good, 21% had intermediate and 46% had poor cytogenetic risk disease at diagnosis. 18 There was no difference in cytogenetic risk or disease status among MSD or UCB recipients. A total of 13 patients with AML had a preceding diagnosis of MDS (MSD-3, UCB-10).
In univariate analyses, outcomes of MSD and UCB HCT were similar (Table 2 and Figure 1) . In multivariate analyses, donor source had no impact on risks of OS, LFS, relapse or TRM. Compared with MSD, the relative risks for UCB recipients for OS were 1.3 (95% confidence intervals, 0.8-2.3, P ¼ 0.34), for LFS were 1.2 (0.7-2.1, P ¼ 0.44), for relapse were 0.7 (0.3-1.3, P ¼ 0.23) and for In unadjusted analyses, graft source had no impact on the cumulative incidences of grades 2-4 or grades 3-4 acute GVHD. The cumulative incidence of neutrophil engraftment by day 42 post-transplantation was lower for patients who received UCB HCT (85% vs 100% for MSD, Po0.01). UCB HCT recipients had a lower incidence of chronic GVHD at 2-years post-transplant (61 vs 33% for MSD, P ¼ 0.04). Among 21 MSD HCT recipients with chronic GVHD, 76% presented as classic and 24% as overlap syndrome as classified according to National Institutes of Health criteria; 19 chronic GVHD severity was mild in 10%, moderate in 76% and severe in 14% of patients. Among 20 UCB HCT recipients with chronic GVHD, presentation was as classic syndrome in 40% and as overlap syndrome in 60% of patients; 10% had mild, 80% had moderate and 10% had severe chronic GVHD. Figure 2 shows ALC recovery post-transplantation for our cohort. Compared with MSD HCT, recipients of UCB had significantly lower ALC counts at day 14 and day 28, but there was no difference in ALC counts at day 60 and day 100.
Discussion
Our study highlights the feasibility of using 4-6/6 HLAmatched UCB as a donor source for RIC HCT among patients with AML or MDS aged 55-70 years, who do not have an HLA-identical sibling donor. Together, the use of RIC and UCB extend the availability of transplant therapy to older patients previously excluded on the basis of age and lack of a suitable MSD.
UCB recipients had a significantly lower cumulative incidence of chronic GVHD (33 vs 61%). Given the relatively small sample size, we did not consider chronic GVHD in multivariate models. A greater proportion of UCB recipients received anti-thymocyte globulin as a part of their conditioning regimen, which may in part explain their decreased risk of chronic GVHD. 20, 21 We and other investigators have previously reported lower risks of chronic GVHD with UCB compared with other donor sources. 8, [22] [23] [24] This may greatly reduce the morbidity and any continuing medical disability among UCB recipients, particularly compared with the higher risks of chronic GVHD that accompany matched unrelated donor HCT. 22, 23 Cell dose is a critical determinant of engraftment and transplant outcomes following UCB transplantation. We have previously reported on the safety and efficacy of double unit UCB transplantation in both the myeloablative and RIC settings. 2, 3, 10 In this study, the majority (95%) of UCB recipients received two UCB units with acceptable outcomes, supporting the use of this approach in older patients. Furthermore, a recent analysis from our institution suggests that the transplantation of two partially HLA-matched UCB units may be associated with enhanced graft-versus-leukemia activity and lower risks of leukemia relapse compared with single unit UCB HCT. 25 We did not have a sufficient number of unrelated donor HCT recipients for comparison with UCB transplantation; only five patients older than 55 years received a RIC HCT using a matched unrelated donor for AML or MDS at our institution during the study period. As UCB is primarily being investigated as an alternative graft source for patients who do not have a sibling donor, studies comparing its outcomes with unrelated donor transplantation in older patients are still needed. The rapid availability of UCB and the lower risks of chronic GVHD despite using HLAmismatched units are some advantages that make UCB an attractive alternative donor source over unrelated donors among older patients with high-risk AML and MDS. Irrespective of the pros and cons of both donor sources, increasing availability of both unrelated donors and UCB is expected to make allogeneic HCT available as a treatment option to a greater number of older patients who were previously not offered HCT because of a lack of suitable donor.
The relatively small sample size is another shortcoming of our study. Our findings have to be confirmed in analyses that include larger cohorts of patients through controlled clinical trials or registry-based analyses, especially with matched unrelated donor and haplo-identical transplant comparison groups. The prospective selection criteria for transplantation, use of a homogeneous conditioning and GVHD prophylaxis regimen and use of common supportive care and follow-up protocols are strengths of our study.
In conclusion, our study shows the feasibility of HLAmismatched UCB as an alternative graft source for older patients with AML and MDS who do not have an HLAidentical sibling donor and require allogeneic HCT.
